Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT ID: NCT06747611

Last Updated: 2025-09-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-21
• Study Completion Date: 2028-03-15

Brief Summary

Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the United States alone, including males and females across all ethnic groups, with a lifetime risk of 2.1%. Autoimmunity develops against the hair follicle, resulting in non-scarring hair loss that may begin as patches that can coalesce and progress to cover the entire scalp (alopecia totalis) or eventually the entire body (alopecia universalis). In AA, there is no permanent destruction of the hair follicle, and regrowth remains possible. Treatment options for AA include intralesional steroids, topical anthralin, allergic contact dermatitis with diphencyprone (DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE), and recently janus kinase ( JAK) inhibitors. Despite the recent approval of JAKs for the treatment of extensive alopecia areata, some patients are treatment resistant, suffer relapses, or cannot take an oral immunosuppressive medication.

This study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.

Conditions

Alopecia Areata; Alopecia Totalis; Alopecia Universalis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Alopecia Areata study group

randomized to receive antibiotics and MTT oral capsule

Group Type: EXPERIMENTAL

Vancomycin, Neomycin and MTT capsules

Intervention Type: DRUG

patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.

Alopecia Areata control group

randomized to receive placebo antibiotics and placebo MTT oral capsule

Group Type: PLACEBO_COMPARATOR

Placebo capsules

Intervention Type: DRUG

patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.

Interventions

Vancomycin, Neomycin and MTT capsules

patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.

Intervention Type: DRUG

Placebo capsules

patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients 18 to 75 years of age with moderate to severe alopecia areata (SALT score >30%).
• Patients with a diagnosis of patch type alopecia areata, totalis, or universalis..
• Duration of hair loss >=3 months..
• No evidence of active, ongoing regrowth present at baseline.
• Females of childbearing potential must have a negative urine or serum pregnancy test at screening and immediately prior to MTT.
• Females of childbearing potential must agree to use an effective form of contraception from 14 days prior to study antibiotics through at least 30 days after MTT. Acceptable forms of contraception include oral or intramuscular contraceptives, intrauterine devices, surgical sterilization.
• Participants are not enrolled in another clinical study.
• If undergoing treatment with a JAK inhibitor, participant is willing to discontinue treatment for 1 month prior to enrollment and throughout the duration of the study.

Exclusion Criteria

• Active gastrointestinal infection at time of enrollment.
• Having been administered antibiotics in the last 48 hours.
• Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to treatment..
• Requires continued antibiotic use
• Allergy to study antibiotics (vancomycin, neomycin).
• Known or suspected severe gastrointestinal dysmotility disorder, e.g., gastroparesis, pseudo-obstruction, scleroderma with gastrointestinal involvement
• Ileus or small bowel obstruction.
• Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy.
• History of total colectomy.
• Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy.
• Unable or unwilling to comply with protocol requirements.
• Expected life expectancy < 6 months.
• Previous MTT or microbiome-based products at any time excluding this study.
• History of severe anaphylactic or anaphylactoid food allergy.
• Solid organ transplant recipients 90 days post-transplant or on active treatment for rejection.
• A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.
• History of or existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis and patients with evidence of infection or skin cancer in the treated areas.
• Patients in whom the diagnosis of alopecia areata is questionable.
• Patients in whom regrowth is present/evident at baseline in the areas to be treated.
• Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma of the skin) which in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.
• Patients unwilling or unable to discontinue treatments known to affect hair regrowth in alopecia areata.
• Patients who have been treated with intralesional steroids, systemic steroids, anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil, JAK inhibitors or other medication which in the opinion of the investigator may affect hair regrowth, within one month of the baseline visit..
• Patients determined by the investigator to have extreme diets..
• Pregnant and breastfeeding females..

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Columbia University

OTHER

Sponsor Role: collaborator

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria K Hordinsky, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

John Meisenheimer

Role: CONTACT

jmeisenh@umn.edu

612-625-2624

Facility Contacts

John Meisenheimer

Role: primary

jmeisenh@umn.edu

612-626-9183

Other Identifiers

DERM-2022-30819

Identifier Type: -

Identifier Source: org_study_id